Pre-Meeting Survey

1. What treatments do you commonly use when managing your patients with eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome (HES)? (Multiple answers are allowed) *

2. How important are the following treatment goals when you are managing a patient with EGPA/HES? *

• Remission of disease
• Normalisation of biomarker levels e.g., blood eosinophils
• Prevention of symptomatic relapses
• Steroid elimination (or reduction to the lowest dose)
• No drug-induced side effects

3. Do you agree that it is important to avoid prolonged use of OCS or GC when managing a patient with EGPA/HES? *

4. How often do you work with your peers from other specialties (e.g., Pulmonology, Rheumatology) when managing patients with EGPA/HES? *

5. Do you agree that the interleukin 5 (IL5) signalling pathway plays an important role in eosinophilic diseases such as severe eosinophilic asthma, EGPA, and HES? *